FDA advisory committee narrowly backs Glaxo OTC nicotine spray

In a close 8-7 vote, the FDA’s Nonprescription Drugs Advisory Committee backed the efficacy of GlaxoSmithKline’s (GSK) over-the-counter (OTC) nicotine oral spray as a smoking cessation aid in adults who are trying to quit smoking.

Update: The committee voted 9-6 in favor of the safety profile.

Update: The committee voted 9-6 in favor of the risk/benefit profile in an OTC setting.

https://seekingalpha.com/news/3500270-fda-advisory-committee-narrowly-backs-glaxo-otc-nicotine-spray